HCA 8-K Current Reports

Earnings & ResultsRegulation FDExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 24, 2026)

HCA Healthcare reported second-quarter 2026 results that beat on the top line and grew Adjusted EBITDA 4.6% to $4.027 billion, but the quality of that growth is mixed. Revenue rose 8.7% to $20.230 billion and diluted EPS rose 11.6% to $7.62. However, the results were helped by roughly $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, primarily Florida, including a one-time $1.372 billion revenue catch-up tied to periods back to October 2024. Against that, management estimates an unfavorable payer mix shift from uninsured volume tied to exchange coverage losses of about $400 million in the quarter, and surgical volumes declined (inpatient surgeries down 2.3%, outpatient down 3.4%). The most important change for investors is the revised 2026 guidance. Net income attributable to HCA was cut to $6.300-$6.700 billion from $6.495-$7.035 billion, and EPS guidance was lowered to $28.70-$30.50 from $29.10-$31.50. Adjusted EBITDA guidance fell to $15.400-$16.100 billion. The exchange-related headwind estimate was widened to ($1.0)-($1.2) billion from ($600)-($900) million, while the Medicaid supplemental payment benefit was raised to $300-$500 million from a ($50)-($250) million range. Revenue guidance was narrowed to $77.0-$79.5 billion. Management characterized the Q2 results as consistent with its July 14 preview, which suggests the cut was already anticipated by the market. Capital allocation remains shareholder-friendly but leverage is rising. HCA repurchased 4.752 million shares for $2.064 billion in the quarter, leaving $7.210 billion of authorization, and declared a quarterly dividend of $0.78 per share payable September 30, 2026. Total debt reached $49.718 billion against cash of $1.013 billion, and operating cash flow fell sharply to $2.335 billion from $4.210 billion a year earlier. Investors should weigh the strong earnings headline against lower cash generation, the reliance on one-time supplemental payment catch-ups, and a meaningful deterioration in the exchange-driven payer mix outlook.

Jul 24, 2026 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 14, 2026)

HCA Healthcare previewed preliminary second-quarter 2026 results and revised its full-year 2026 guidance. Revenue for Q2 2026 is expected to be about $20.23 billion, up from $18.605 billion a year earlier (roughly 8.7% growth). Net income attributable to HCA is expected at about $1.699 billion, or $7.62 per diluted share, versus $6.83 in Q2 2025. Adjusted EBITDA is expected at about $4.027 billion, up from $3.849 billion, though the adjusted EBITDA margin contracted to 19.9% from 20.7%. These figures are preliminary, unaudited, and subject to the completion of the quarter-end close. The quarter was shaped by two offsetting forces. Uninsured volume rose as patients lost coverage on the health insurance exchanges, an unfavorable payer mix shift that management estimates reduced pre-tax income by about $400 million, including a roughly $75 million increase to its prior first-quarter exchange estimate. Partly offsetting this, HCA recognized about $400 million of incremental net Medicaid supplemental payment benefit, primarily from Florida's state directed payment program approved by CMS during the quarter. Volume trends were mixed: admissions and emergency room visits grew, while inpatient and outpatient surgeries declined. HCA lowered its 2026 guidance. Revenue is now expected at $77.0 to $79.5 billion (previously $76.5 to $80.0 billion), net income at $6.3 to $6.7 billion (previously $6.495 to $7.035 billion), adjusted EBITDA at $15.4 to $16.1 billion (previously $15.55 to $16.45 billion), and diluted EPS at $28.70 to $30.50 (previously $29.10 to $31.50). The estimated exchange headwind widened to $1.0 to $1.2 billion from $600 to $900 million, while the Medicaid supplemental payment benefit moved to a $300 to $500 million tailwind from a net headwind of $50 to $250 million. Capital expenditure guidance of $5.0 to $5.5 billion is unchanged. Management will discuss results on a July 24, 2026 earnings call.

Jul 14, 2026 8-K

Leadership Changes

HCA Healthcare, Inc. 8-K Report, Executive Changes (Jun 18, 2026)

HCA Healthcare, Inc. has announced a significant leadership change with the upcoming departure of Dr. Michael Cuffe from his role as Executive Vice President and Chief Clinical Officer. This transition is effective August 31, 2026, after which Dr. Cuffe will remain with the company in a transitional capacity until February 2027. This move signifies a shift in the company's executive team, and investors will want to monitor the strategic implications and the appointment of a successor to this critical clinical leadership position.

Jun 18, 2026 8-K

Material AgreementsFinancial EventsOther Events+1

HCA Healthcare, Inc. 8-K Report, Material Agreement (Apr 30, 2026)

HCA Healthcare, Inc. (HCA) announced through its subsidiary, HCA Inc., the successful completion of a public offering of $3 billion in aggregate principal amount of senior unsecured notes. The offering is comprised of three tranches: $1 billion of 4.700% Senior Notes due 2031, $750 million of 5.000% Senior Notes due 2033, and $1.25 billion of 5.300% Senior Notes due 2036. These notes are guaranteed on a senior unsecured basis by the Parent Guarantor, HCA Healthcare, Inc. This significant debt issuance, registered under a shelf registration statement, will increase HCA's leverage but provides substantial capital. Investors should note the varying interest rates and maturity dates, which reflect market conditions and the company's long-term financing strategy. The company has entered into an underwriting agreement with several major investment banks for this offering, and detailed terms, including covenants, optional redemption, and change of control provisions, are outlined in the respective indentures filed with the SEC.

Apr 30, 2026 8-K

Shareholder Matters

HCA Healthcare, Inc. 8-K Report, Shareholder Vote Results (Apr 28, 2026)

HCA Healthcare, Inc. (HCA) filed an 8-K on April 28, 2026, detailing the results of its Annual Meeting of Stockholders held on April 23, 2026. The meeting saw strong participation, with over 209 million shares represented. A key outcome was the overwhelming election of all nine director nominees to the Board of Directors, indicating robust shareholder confidence in the current leadership and governance structure. Furthermore, the Company's appointment of Ernst & Young LLP as its independent registered public accounting firm for 2026 received broad ratification, underscoring shareholder trust in the auditing process. Shareholder approval was also given to the advisory resolution on executive compensation, suggesting alignment between management's pay practices and investor sentiment. However, two shareholder proposals, one concerning healthcare consequences reporting and another on shareholders' right to act by written consent, failed to gain majority support.

Apr 28, 2026 8-K

HCA Healthcare, Inc. 8-K Report, Corporate Update (Apr 27, 2026)

HCA Healthcare, Inc. (NYSE: HCA) announced on April 27, 2026 that its wholly owned subsidiary, HCA Inc. (the Issuer), is launching a proposed public offering of senior unsecured notes. The final size, maturity, and coupon will depend on market conditions at pricing. Citigroup, Barclays, BofA Securities, and J.P. Morgan are joint book-running managers, and the offering is being made under an effective shelf registration statement. The filing does not state a final offering size, so investors should treat the amount as undetermined until pricing. The company says net proceeds are intended for general corporate purposes, including repaying borrowings under its $4.000 billion commercial paper program (which can be reborrowed), and potentially funding redemptions of its 5.250% senior notes due June 2026 ($1.500 billion) and 5.375% senior notes due September 2026 ($1.000 billion). The Issuer has elected to redeem both series on May 27, 2026, conditioned on receipt of offering proceeds before that date. The redemption is effectively a refinancing of near-term maturities, which would reduce 2026 debt maturities and extend the company's debt profile if completed. For investors, the filing is primarily a financing and liability-management event rather than an operating update, and it contains no new financial results or guidance. Key items to monitor are the pricing terms (coupon and tenor), the final principal amount relative to the $2.500 billion of notes being redeemed, and whether the conditional redemption closes on schedule. The filing refers to the Form 10-K filed February 10, 2026 for risk factors.

Apr 27, 2026 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Apr 24, 2026)

HCA Healthcare reported first quarter 2026 results that were mixed beneath a headline EPS gain. Revenue rose 4.3% to $19.109 billion, and diluted EPS increased 10.9% to $7.15, but that EPS growth was driven largely by a sharply lower share count (226.7 million diluted shares versus 249.4 million a year earlier, reflecting about $1.57 billion of buybacks). Net income attributable to HCA grew only 0.6% to $1.620 billion, and Adjusted EBITDA rose just 1.9% to $3.802 billion, with the Adjusted EBITDA margin contracting from 20.4% to 19.9%. Operating volumes were soft. Same facility admissions rose 0.9% and equivalent admissions rose 1.3%, but inpatient surgeries fell 0.3%, outpatient surgeries fell 1.7%, and the company did not see its typical seasonal first-quarter volume increase. Respiratory-related admissions fell 42% year over year, and a January winter storm also weighed on volumes. Management said these headwinds were mostly offset by recognition of Medicaid supplemental program revenue that was not in its initial 2026 guidance. Pricing was the main growth driver, with same facility revenue per equivalent admission up 3.1%. Salaries and benefits and other operating expenses grew faster than revenue, which compressed margins. Cash generation and capital return were strong. Operating cash flow rose 22.0% to $2.014 billion, and the company repurchased $1.571 billion of stock. Total debt stood at $48.0 billion, with $8.5 billion of short-term borrowings and debt due within one year, up from $4.9 billion at year-end. The company reaffirmed its 2026 guidance of $76.5–80.0 billion in revenue, $15.55–16.45 billion in Adjusted EBITDA, and $29.10–31.50 in diluted EPS, and declared a quarterly dividend of $0.78 per share payable June 30, 2026.

Apr 24, 2026 8-K

HCA Healthcare, Inc. 8-K Report, Executive Changes (Feb 25, 2026)

HCA Healthcare, Inc. (HCA) announced the adoption of its 2026 Executive Officer Performance Excellence Program (Executive Officer PEP) on February 24, 2026. This program outlines how the company's executive officers will be eligible to earn performance-based cash awards. The compensation structure is heavily weighted towards financial performance, with 80% of awards tied to EBITDA targets and 20% linked to quality metrics. This emphasis signals a continued focus on profitability while also incorporating critical patient care and experience indicators. Investors should note the specific award opportunities, which range from 175% of base salary for the CEO down to 100% for other named executive officers. The program details tiered payouts for EBITDA performance, with potential for awards to double the target amount at maximum performance. The quality metrics component is also subject to tiered payouts and can be forfeited entirely if EBITDA falls below 90% of target, reinforcing the primacy of financial results. The Compensation Committee retains discretion over adjustments and clawbacks, providing flexibility and risk mitigation.

Feb 25, 2026 8-K

Material AgreementsFinancial EventsOther Events+1

HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 27, 2026)

HCA Healthcare reported fourth-quarter 2025 results on January 27, 2026 that beat its own trajectory on the bottom line. Q4 revenue rose 6.7% to $19.513 billion, GAAP net income attributable to HCA grew 30.6% to $1.878 billion, and diluted EPS rose 44.6% to $8.14. Excluding facility gains and losses, EPS, as adjusted, rose 28.8% to $8.01, and Adjusted EBITDA grew 10.8% to $4.114 billion (21.1% margin). Operating volumes were solid: same facility admissions rose 2.4%, same facility equivalent admissions rose 2.5%, and revenue per equivalent admission rose 2.9%. Comparisons are flattered by roughly $200 million (about $0.60 per share) of Hurricane Helene and Milton impacts in Q4 2024, and Q4 2024 also carried a $195 million facility loss. Full-year 2025 revenue was $75.6 billion, net income attributable to HCA was $6.784 billion ($28.33 diluted EPS), and Adjusted EBITDA was $15.566 billion. Cash generation and capital allocation are the key points for investors. Q4 operating cash flow fell to $2.359 billion from $2.559 billion, but that figure was depressed by about $1.3 billion of tax payments deferred into Q4 because of IRS relief tied to April 2025 Tennessee severe weather. Full-year operating cash flow was $12.636 billion, and capex was $4.944 billion. HCA repurchased $10.067 billion of stock during 2025, including $2.558 billion in Q4. The Board authorized a new $10 billion repurchase program with no time limit, and declared a $0.78 quarterly dividend payable March 31, 2026. Total debt was $46.492 billion at year end, against cash of $1.040 billion. Leverage is high relative to the equity base, since stockholders' deficit attributable to HCA widened to $(6.027) billion. For 2026, management guided to revenue of $76.5 to $80.0 billion, Adjusted EBITDA of $15.55 to $16.45 billion, and diluted EPS of $29.10 to $31.50 on about 223.5 million shares. Capex is expected at $5.0 to $5.5 billion. The guidance assumes a mostly stable operating environment and excludes facility gains and losses, debt retirement losses, legal claim costs, and impairments. It also reflects headwinds from the expiration of enhanced ACA marketplace premium tax credits at year end 2025, the OBBBA, tariffs, and uncertain Medicaid supplemental payments. The guided EPS midpoint of about $30.30 implies modest growth over 2025's $28.33, helped by a lower share count.

Jan 27, 2026 8-K

HCA Healthcare, Inc. 8-K Report, Material Agreement (Oct 31, 2025)

HCA Healthcare, Inc. (HCA) announced the successful completion of a significant public offering of senior notes, raising a total of $3.25 billion. The offering was structured across four tranches with varying maturities and coupon rates: $500 million of 4.300% Senior Notes due 2030, $1 billion of 4.600% Senior Notes due 2032, $1 billion of 4.900% Senior Notes due 2035, and $750 million of 5.700% Senior Notes due 2055. These notes are guaranteed by the parent company, HCA Healthcare, Inc., and represent senior unsecured obligations of the subsidiary issuer. The proceeds from this offering will likely be used to fund general corporate purposes or existing debt refinancing, though specific use of proceeds is not detailed in this filing. The company has also entered into an underwriting agreement with several prominent financial institutions to facilitate this issuance. This move indicates HCA's ongoing strategy to manage its capital structure and potentially fund future growth or operational needs.

Oct 31, 2025 8-K

HCA Healthcare, Inc. 8-K Report, Corporate Update (Oct 27, 2025)

On October 27, 2025, HCA Healthcare, Inc. disclosed via Form 8-K that its wholly owned subsidiary, HCA Inc. (the Issuer), is launching a proposed public offering of senior unsecured notes. Final terms, including maturity, interest rate, and principal amount, will depend on market conditions at pricing. The filing is a financing and liability-management event rather than an operating or earnings update, so it contains no new financial results, guidance, or operating metrics. The stated use of proceeds is general corporate purposes, which may include repaying borrowings under HCA's $4.0 billion commercial paper program (which can be reborrowed) and redeeming part or all of HCA Inc.'s $1.5 billion of 5.875% senior notes due 2026. The Issuer has elected to redeem all $1.5 billion of those notes on November 26, 2025, conditioned on receipt of the offering's net proceeds before the redemption date. The 8-K itself is not a formal redemption notice; that is issued separately. For investors, the transaction appears to be a refinancing that extends the maturity profile and shifts short-term or near-term debt into longer-dated fixed-rate notes. Its net effect on leverage and interest expense depends on final pricing and whether the commercial paper is repaid or only refinanced. The offering is made under an effective shelf registration, and the 8-K notes that the forward-looking statements and risk factors in HCA's February 14, 2025 Form 10-K still apply.

Oct 27, 2025 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Oct 24, 2025)

HCA Healthcare reported third-quarter 2025 results that beat its own prior trajectory and raised full-year 2025 guidance. Revenue rose 9.6% year over year to $19.161 billion, and net income attributable to HCA grew 29.4% to $1.643 billion, or $6.96 per diluted share (up 42.6%). Adjusted EBITDA increased 18.5% to $3.870 billion, with the margin expanding to 20.2% from 18.7%. Operating volume was steady-to-better: same facility admissions rose 2.1%, same facility equivalent admissions rose 2.4%, and same facility revenue per equivalent admission increased 6.6%. Part of the year-over-year comparison benefits from Q3 2024 being depressed by roughly $50 million (about $0.15 per share) of Hurricane Helene impacts. Management raised 2025 guidance across the board. Revenue is now expected at $75.0 to $76.5 billion (previously $74.0 to $76.0 billion), Adjusted EBITDA at $15.25 to $15.65 billion (previously $14.7 to $15.3 billion), and diluted EPS at $27.00 to $28.00 (previously $25.50 to $27.00). Capital expenditures are estimated at about $5.0 billion. Cash generation was strong, with operating cash flow of $4.416 billion in the quarter. HCA also repurchased 6.514 million shares for $2.498 billion and retains $3.256 billion under its authorization, while the board declared a $0.72 quarterly dividend payable December 29, 2025. The balance sheet carries meaningful leverage: total debt of $44.511 billion against cash of $997 million, and stockholders' deficit attributable to HCA widened to $(5.335) billion. Investors should weigh the strong earnings and buyback-driven per-share growth against this leverage and ongoing policy risks, including the scheduled expiration of enhanced ACA premium tax credits after December 31, 2025, Medicaid funding changes under the One Big Beautiful Bill Act, and sequestration.

Oct 24, 2025 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 25, 2025)

HCA Healthcare reported strong second-quarter 2025 results, with revenues up 6.4% to $18.605 billion and net income attributable to HCA up 13.1% to $1.653 billion. Diluted EPS rose 23.5% to $6.83, and adjusted EBITDA increased 8.4% to $3.849 billion, with the adjusted EBITDA margin expanding to 20.7% from 20.3%. Operating cash flow more than doubled to $4.210 billion from $1.971 billion. EPS growth outpaced net income growth largely because diluted shares fell about 8% year over year, from 264.1 million to 241.9 million, reflecting aggressive buybacks. Same facility admissions grew 1.8%, and same facility revenue per equivalent admission rose 4.0%, so pricing and mix contributed more to growth than volume. Management raised its 2025 guidance across the board. Revenue is now expected at $74.0 to $76.0 billion, adjusted EBITDA at $14.7 to $15.3 billion, and diluted EPS at $25.50 to $27.00, up from $24.05 to $25.85. The midpoint EPS raise is roughly 6%. Capital expenditures are estimated at about $5.0 billion. The Board declared a quarterly dividend of $0.72 per share, payable September 30, 2025 to holders of record on September 16, 2025. Balance sheet leverage remains high. Total debt was $44.5 billion against $939 million of cash, and HCA reported a stockholders' deficit attributable to the company of $4.4 billion, which widened from $2.5 billion at year-end 2024. Short-term debt and current maturities rose to $5.1 billion. Investors should weigh strong cash generation and shareholder returns, including $5.0 billion of repurchases in the first half, against this leverage and the policy and payer uncertainties cited in the forward-looking statements, such as enhanced premium tax credit expirations, Medicaid program changes, and the OBBBA legislation.

Jul 25, 2025 8-K

Financial EventsOther Events

HCA Healthcare, Inc. 8-K Report, Executive Changes (Jul 11, 2025)

HCA Healthcare, Inc. (NYSE: HCA) filed a Form 8-K on July 11, 2025 to disclose a board change. The Board appointed John W. Chidsey, III as an independent director effective July 15, 2025, expanding the Board from nine to ten members. Mr. Chidsey will serve on the Audit and Compliance, Compensation, and Patient Safety and Quality of Care Committees. The filing is limited to governance information and contains no financial results, guidance, or material operational updates. Mr. Chidsey brings a substantial corporate background. He most recently served as global chief executive officer of Subway, previously led Burger King Holdings as CEO, and held leadership roles at Cendant Corporation and senior financial positions at PepsiCo. He currently sits on the board of Norwegian Cruise Line Holdings and formerly served on the boards of Encompass Health, Burger King Holdings (as chairman), and Brinker International. His financial and strategic expertise may strengthen oversight of HCA's audit and compensation functions. For investors, the appointment is a routine, non-dilutive governance event. The filing states there is no arrangement or related-party transaction requiring disclosure, and Mr. Chidsey will receive the standard non-management director compensation previously described in HCA's April 29, 2025 8-K. The appointment should be viewed as a modest governance enhancement rather than a signal of changed strategy or financial performance.

Jul 11, 2025 8-K

HCA Healthcare, Inc. 8-K Report, Financial Obligation (Jun 10, 2025)

HCA Healthcare, Inc. (HCA) has announced the establishment of a commercial paper program through its direct, wholly-owned subsidiary, HCA Inc. This program allows for the issuance of unsecured commercial paper notes up to a maximum aggregate principal amount of $4.0 billion outstanding at any time. The Parent Guarantor, HCA Healthcare, Inc., is providing an unconditional guarantee for these notes, indicating strong financial backing for this new financing facility. The primary purpose of this commercial paper program is to provide HCA with flexible access to short-term funding for general corporate purposes. The notes will have maturities of up to 397 days and will be sold on customary terms in the U.S. commercial paper market. Investors should note that this is a private placement and the securities are not registered under the Securities Act of 1933, meaning they are subject to specific exemptions from registration requirements. This move suggests a proactive approach by HCA to manage its liquidity and working capital needs.

Jun 10, 2025 8-K

Leadership ChangesShareholder MattersCorporate Changes+1

HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 29, 2025)

HCA Healthcare, Inc. filed an 8-K on April 28, 2025, detailing key corporate governance updates approved at their Annual Meeting on April 24, 2025. The most significant information for investors pertains to changes in Board of Directors compensation and an expansion of the company's stock incentive plan. The Board approved a new compensation program for non-management directors, which includes revised annual retainers for various committee roles and the Chairmanship, along with a significant annual equity award valued at $220,000 in restricted stock units. This reflects an alignment with attracting and retaining experienced leadership. Furthermore, HCA stockholders overwhelmingly approved an amendment to the 2020 Stock Incentive Plan, increasing the share pool by 13,150,000 shares and extending its term to 2035. This provides the company with substantial equity to incentivize future performance and employee retention. Additionally, an amendment to the Certificate of Incorporation to exculpate officers was approved, offering further protection to management. The filing also confirms the election of all nine director nominees and the ratification of Ernst & Young LLP as the independent auditor.

Apr 29, 2025 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Apr 25, 2025)

HCA Healthcare reported first quarter 2025 results (quarter ended March 31, 2025) with revenues of $18.321 billion, up from $17.339 billion a year earlier, and net income attributable to HCA of $1.610 billion, or $6.45 per diluted share, versus $5.93 in the prior-year quarter. The prior-year figure included $201 million in facility sale gains ($0.57 per share), so on an adjusted basis EPS grew from $5.36 to $6.45, roughly 20 percent. Adjusted EBITDA rose to $3.733 billion from $3.353 billion, with the margin expanding to 20.4 percent from 19.3 percent. Volume trends were solid: same facility admissions rose 2.6 percent, same facility equivalent admissions rose 2.8 percent, emergency room visits rose 4.0 percent, and same facility revenue per equivalent admission increased 2.9 percent. Outpatient surgery cases declined 2.1 percent on a same facility basis, a soft spot in the quarter. Cash generation weakened in the quarter. Operating cash flow fell to $1.651 billion from $2.469 billion, driven largely by a $1.000 billion outflow from accounts payable and accrued expenses. Capital expenditures were $991 million. HCA returned substantial capital to shareholders, repurchasing 7.762 million shares for $2.506 billion, leaving $8.259 billion under its authorization. Total debt stood at $44.576 billion against cash of $1.060 billion, and stockholders' deficit widened to $(3.519) billion attributable to HCA. Leverage and the buyback pace relative to free cash flow are the key watch items for investors. Management reaffirmed 2025 guidance issued in January: revenues of $72.8 to $75.8 billion, Adjusted EBITDA of $14.3 to $15.1 billion, and diluted EPS of $24.05 to $25.85. The board declared a quarterly dividend of $0.72 per share, payable June 30, 2025 to holders of record on June 16, 2025. Guidance assumes a mostly stable operating environment and flags risks including tariffs, Medicaid and Medicare policy changes, expiring enhanced ACA premium tax credits, and lingering impacts from the 2024 hurricanes.

Apr 25, 2025 8-K

Material AgreementsFinancial EventsOther Events+1

HCA Healthcare, Inc. 8-K Report, Executive Changes (Feb 24, 2025)

HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing its 2025 Executive Officer Performance Excellence Program (Executive Officer PEP). This new program outlines the performance-based compensation structure for the company's executive officers, aiming to align their incentives with key financial and operational goals. The program emphasizes achievement of EBITDA targets, which represent 80% of the award opportunity, and quality metrics, accounting for the remaining 20%. This structure suggests a strong focus on profitability and operational efficiency, while also incorporating critical quality of care indicators as defined by the company. For investors, the most significant aspect is the direct link between executive compensation and the achievement of specific financial and quality benchmarks. The program details the potential payout percentages based on performance levels, ranging from threshold to maximum achievement, with specific award opportunities tied to base salary for the CEO, CFO, and COO. The inclusion of stringent conditions, such as a minimum EBITDA performance being required for any quality-based payout, underscores the company's commitment to balancing financial success with patient care excellence. The filing also notes the retirement of a Board member, Meg G. Crofton, effective at the upcoming annual meeting.

Feb 24, 2025 8-K

HCA Healthcare, Inc. 8-K Report, Material Agreement (Feb 21, 2025)

HCA Healthcare, Inc. (HCA) has announced the completion of a significant debt offering, raising $5.25 billion in aggregate principal amount of senior notes through its wholly owned subsidiary, HCA Inc. This offering comprises six tranches with varying maturities and interest rates, including senior notes due 2028, 2030, 2032, 2035, and 2055, as well as floating rate senior notes due 2028. These notes are guaranteed on a senior unsecured basis by HCA Healthcare, Inc. and are intended to provide additional financial flexibility for the company. The issuance was completed on February 21, 2025, under the company's existing shelf registration statement and pursuant to multiple supplemental indentures. The specific terms, including interest rates and payment dates, are detailed for each tranche. The notes rank senior to subordinated debt and equally to other senior indebtedness of the Issuer, but are effectively subordinated to secured debt and structurally subordinated to the debt of HCA's subsidiaries. Covenants within the indentures place limitations on liens, sale-leaseback transactions, and asset disposals. Additionally, provisions for optional redemption, change of control triggers with a repurchase price of 101%, and events of default are outlined.

Feb 21, 2025 8-K

Material AgreementsFinancial EventsExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Material Agreement (Feb 20, 2025)

HCA Healthcare, Inc. (HCA) announced through its subsidiary, HCA Inc., the entry into a new, larger senior unsecured revolving credit facility totaling $8.0 billion. This new facility has a five-year term and replaces the company's previous senior secured credit facilities, which included a $3.5 billion revolving credit facility and a $1.238 billion term loan. The company repaid all outstanding obligations under the terminated senior secured facilities immediately prior to entering the new agreement. The refinancing is intended to provide HCA with enhanced financial flexibility for general corporate purposes.

Feb 20, 2025 8-K

HCA Healthcare, Inc. 8-K Report, Corporate Update (Feb 18, 2025)

HCA Healthcare's wholly owned subsidiary, HCA Inc. (the Issuer), announced a proposed public offering of senior unsecured notes on February 18, 2025. The filing describes a refinancing package rather than a new growth initiative. As of February 14, 2025, the Issuer had borrowed $2.950 billion under its ABL credit facility, part of which was used to repay at maturity the full $2.600 billion of 5.375% Senior Notes due 2025. The Issuer intends to terminate its existing secured Cash Flow and ABL credit facilities, which mature June 30, 2026 absent termination, and replace them with an $8.000 billion, five-year senior unsecured revolving credit facility. The Cash Flow facility carried $1.238 billion of term loan A outstanding at December 31, 2024. For investors, the key changes are a shift from secured to unsecured debt and a move away from guarantees. The new facility will not be guaranteed by HCA Healthcare or any subsidiary of the Issuer, and it will carry a quarterly maximum leverage covenant of 4.50x, which can step up to 5.00x for certain periods after a material acquisition. Initial pricing is expected at Term SOFR plus 1.25% plus a 0.10% credit spread adjustment, with the margin tied to the Issuer's credit rating going forward. Net proceeds from the notes are earmarked for general corporate purposes, including repaying borrowings under the new facility, or under the ABL facility if the refinancing is not completed. Final notes terms, including maturity, coupon, and principal amount, will depend on market conditions at pricing and were not disclosed in this filing. Overall, the transaction is primarily a liability management and maturity-extension exercise. It addresses the 2025 notes maturity and the 2026 secured facility maturities, and it gives HCA more flexible unsecured funding. The filing does not disclose new earnings, cash flow, or operating results, and the terms of the offering remain subject to market conditions.

Feb 18, 2025 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 24, 2025)

HCA Healthcare reported fourth-quarter 2024 revenues of $18.285 billion, up from $17.303 billion a year earlier, and net income attributable to HCA of $1.438 billion, or $5.63 per diluted share, versus $5.93 in 4Q 2023. The GAAP decline is driven largely by a $195 million ($0.59 per share) loss on sales of facilities, primarily tied to the pending sale of a California hospital, and an estimated $0.60 per share hit from Hurricanes Helene and Milton. Adjusted EBITDA rose 2.6% to $3.712 billion, though the margin contracted to 20.3% from 20.9%. Operating volumes were solid: same facility admissions grew 3.0% and same facility equivalent admissions grew 3.1%, while outpatient surgeries fell 1.3%. For full-year 2024, revenue reached $70.603 billion, GAAP diluted EPS was $22.00, and Adjusted EBITDA was $13.882 billion. Capital return is a major theme. HCA repurchased $1.700 billion of stock in the fourth quarter, full-year repurchases totaled $6.042 billion, and the Board authorized a new $10 billion buyback with no time limit. The quarterly dividend was set at $0.72 per share, payable March 31, 2025. Balance sheet leverage remains substantial, with total debt of $43.031 billion against cash of $1.933 billion, and the company held $7.986 billion of credit facility availability. For 2025, management guided to revenue of $72.8 to $75.8 billion, Adjusted EBITDA of $14.3 to $15.1 billion, and diluted EPS of $24.05 to $25.85 on 243 million shares. Capital expenditures are expected at $5.0 to $5.2 billion. The guidance assumes a mostly stable operating environment and excludes gains or losses on facility sales, debt retirement costs, legal claims, and impairments. Investors should weigh the strong cash generation and buyback capacity against heavy debt, regulatory exposure (including Medicaid supplemental payments and expiring enhanced premium tax credits), and continued hurricane-related costs.

Jan 24, 2025 8-K

Material AgreementsFinancial EventsExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Financial Results (Oct 25, 2024)

HCA Healthcare's third quarter 2024 results (reported October 25, 2024) showed strong top-line and earnings growth. Revenues rose to $17.487 billion from $16.213 billion (about 7.9%), and net income attributable to HCA reached $1.270 billion, or $4.88 per diluted share, versus $3.91 a year earlier. Adjusted EBITDA increased to $3.267 billion from $2.880 billion, with the margin expanding to 18.7% from 17.8%. Volume growth was healthy, with same facility admissions up 4.5% and emergency room visits up 4.6%, while revenue per equivalent admission rose 2.5%. Outpatient surgeries declined 2.0%, a softer spot in the mix. Note that the prior-year quarter included a roughly $397 million Florida directed payment benefit, so the year-over-year comparison is flattered by a non-recurring item in the base period. The main near-term headwind is Hurricanes Helene and Milton. HCA estimated a $50 million (about $0.15 per share) hit in Q3 and expects a further $200 to $300 million (about $0.60 to $0.90 per share) impact in Q4, before any insurance recoveries. Despite this, management reaffirmed 2024 guidance but now expects results in the lower half of the ranges. Guidance calls for Adjusted EBITDA of $13.75 to $14.25 billion and diluted EPS of $21.60 to $22.80. Capital expenditures were raised to about $5 billion. Management also gave early 2025 commentary, suggesting diluted EPS and Adjusted EBITDA growth near or slightly above the upper end of its long-term ranges. Capital allocation remained shareholder-friendly. HCA repurchased 4.948 million shares for $1.795 billion in the quarter, with $2.433 billion left on its authorization, and declared a quarterly dividend of $0.66 per share payable December 27, 2024. Leverage is elevated, however: total debt was $42.965 billion against cash of $2.888 billion, and the balance sheet shows a stockholders' deficit attributable to HCA of $(2.182) billion. Operating cash flow was strong at $3.515 billion in the quarter, up from $2.479 billion a year earlier.

Oct 25, 2024 8-K

HCA Healthcare, Inc. 8-K Report, Material Agreement (Aug 12, 2024)

HCA Healthcare, Inc. (HCA) has filed an 8-K report on August 12, 2024, detailing the completion of a significant public offering of senior notes totaling $3,000,000,000 in aggregate principal amount. This offering consists of three tranches: $750,000,000 of 5.450% Senior Notes due 2031 (New 2031 Notes), $1,250,000,000 of 5.450% Senior Notes due 2034 (2034 Notes), and $1,000,000,000 of 5.950% Senior Notes due 2054 (2054 Notes). These notes are senior unsecured obligations of HCA Inc., guaranteed on a senior unsecured basis by the Parent Guarantor, HCA Healthcare, Inc. The issuance of these notes is a material event for investors as it impacts the company's capital structure and long-term financing. The proceeds from this offering will be used to refinance existing debt and for general corporate purposes, though specific use of proceeds beyond that is not detailed in this filing. The tiered interest rates and maturity dates reflect market conditions and the company's debt management strategy. Investors should note the covenants and change of control provisions detailed in the Indentures, which offer certain protections.

Aug 12, 2024 8-K

HCA Healthcare, Inc. 8-K Report, Corporate Update (Aug 8, 2024)

HCA Healthcare, Inc. (HCA) announced on August 7, 2024, through an 8-K filing, that it has entered into an Underwriting Agreement to issue and sell $3.0 billion in aggregate principal amount of senior notes. This debt offering consists of three tranches: $750 million of 5.450% Senior Notes due 2031, $1.25 billion of 5.450% Senior Notes due 2034, and $1.0 billion of 5.950% Senior Notes due 2054. These notes will be guaranteed on a senior unsecured basis by the Parent Guarantor, HCA Healthcare, Inc., and are being issued under the company's existing Form S-3 registration statement.

Aug 8, 2024 8-K

Leadership ChangesShareholder Matters

HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 23, 2024)

HCA Healthcare reported strong second-quarter 2024 results, with revenues of $17.492 billion (up from $15.861 billion, roughly 10%), net income attributable to HCA of $1.461 billion, or $5.53 per diluted share (versus $4.29 a year earlier), and Adjusted EBITDA of $3.550 billion, a 20.3% margin versus 19.3% in 2Q 2023. Volume trends were healthy: same facility admissions rose 5.8%, same facility equivalent admissions rose 5.2%, and same facility revenue per equivalent admission increased 4.4%. Emergency room visits grew 5.5%, inpatient surgeries rose 2.6%, and outpatient surgeries declined 2.1%. Management characterized demand as strong and raised its full-year 2024 guidance across all key metrics. The revised guidance is the central investor takeaway. Revenue guidance moved to $69.75–$71.75 billion from $67.75–$70.25 billion, net income attributable to HCA to $5.675–$5.975 billion from $5.200–$5.600 billion, Adjusted EBITDA to $13.75–$14.25 billion from $12.85–$13.55 billion, and diluted EPS to $21.60–$22.80 from $19.70–$21.20. Capital expenditures are expected at $5.1–$5.3 billion. Share repurchases remain significant: HCA bought back 4.217 million shares for $1.367 billion in the quarter and had $4.228 billion left under its authorization. Diluted share count fell to 264.1 million from 278.2 million a year earlier, which amplifies per-share earnings growth. Balance sheet and cash generation warrant monitoring. Total debt was $40.880 billion at June 30, 2024, against cash of $831 million, and $4.574 billion of long-term debt comes due within one year. Operating cash flow in the quarter fell to $1.971 billion from $2.475 billion a year earlier, a notable decline that the release does not explain in detail. Liquidity was $7.137 billion of credit facility availability. The Board declared a quarterly dividend of $0.66 per share, payable September 30, 2024 to holders of record on September 16, 2024. Note that the filing's operating cash flow figure for the quarter differs from the six-month figure in the cash flow statement, which is presented separately; investors should rely on the source reconciliation.

Jul 23, 2024 8-K

HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 30, 2024)

HCA Healthcare, Inc. (HCA) filed an 8-K report on April 29, 2024, detailing key events from its Annual Meeting of Stockholders held on April 25, 2024, and a CFO transition. The report announced the retirement of Executive Vice President and CFO William B. Rutherford, effective May 1, 2024, with Christopher F. Wyatt appointed as the new principal accounting officer while continuing his role as Senior Vice President and Controller. This transition appears smooth with no immediate concerns indicated regarding Mr. Wyatt's appointment. The Annual Meeting saw strong stockholder support for the re-election of all ten director nominees and the ratification of Ernst & Young LLP as the independent registered public accounting firm. Furthermore, stockholders approved a non-binding advisory resolution to hold annual say-on-pay votes, aligning with the board's determination to conduct these votes yearly. Conversely, several stockholder proposals concerning risk mitigation for state restrictions on emergency abortions, patient feedback on care quality, and maternal health outcomes were not approved.

Apr 30, 2024 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Apr 26, 2024)

HCA Healthcare reported first quarter 2024 results (quarter ended March 31, 2024) that were driven primarily by broad-based volume growth. Revenues rose 11.2% to $17.339 billion from $15.591 billion, and net income attributable to HCA Healthcare was $1.591 billion, or $5.93 per diluted share, versus $4.85 a year earlier. The headline EPS figure was helped by a $201 million pre-tax gain on facility sales (about $0.57 per diluted share), primarily from the sale of a California hospital. Excluding facility gains and losses, net income attributable to HCA, as adjusted, was $1.437 billion, or $5.36 per diluted share, compared with $4.93 a year earlier, a gain of roughly 9%. Adjusted EBITDA rose 5.7% to $3.353 billion, although the margin contracted to 19.3% from 20.3%, reflecting higher other operating expenses. Operating volumes were strong. Same facility admissions grew 6.2%, same facility equivalent admissions grew 5.2%, and same facility emergency room visits grew 7.2%. Same facility revenue per equivalent admission rose 3.5%. Inpatient surgeries grew 1.7%, while outpatient surgeries declined 2.1%. Operating cash flow was $2.469 billion, up from $1.803 billion. Management reaffirmed its 2024 guidance, which calls for revenues of $67.75 billion to $70.25 billion, net income attributable to HCA of $5.2 billion to $5.6 billion, Adjusted EBITDA of $12.85 billion to $13.55 billion, and diluted EPS of $19.70 to $21.20. Guidance excludes facility gains and losses, debt retirement losses, legal claim costs, and impairments. Capital allocation remained shareholder-focused. HCA repurchased 3.894 million shares for $1.180 billion, leaving $5.595 billion under its authorization, and declared a quarterly dividend of $0.66 per share payable June 28, 2024 to holders of record on June 14, 2024. Total debt was $40.191 billion at quarter end, and HCA issued $4.483 billion of long-term debt during the quarter while repaying $2.066 billion. Liquidity included $1.284 billion of cash and $7.987 billion of credit facility availability. Investors should note the substantial leverage, the thinner adjusted margin, and the reliance on volume growth and continued buybacks.

Apr 26, 2024 8-K/A

Leadership Changes

HCA Healthcare, Inc. 8-K/A Report, Executive Changes (Feb 26, 2024)

This 8-K/A filing from HCA Healthcare, Inc. serves as an amendment to a previous 8-K announcing the appointment of Michael A. Marks as Executive Vice President and Chief Financial Officer, effective May 1, 2024. The primary purpose of this amendment is to disclose material changes to Mr. Marks' compensation arrangements related to his new role, which were not finalized at the time of the initial filing. Key details of the compensation changes include the establishment of the 2024 Executive Officer Performance Excellence Program (Executive Officer PEP). Under this program, Mr. Marks' performance awards will be weighted 80% towards EBITDA targets and 20% towards specific quality metrics. These quality metrics encompass Healthcare-Associated Infections and Sepsis, Complication and Mortality, and Care Experience. His award opportunity will increase from 65% of base salary to 110% of base salary upon assuming the CFO role.

Feb 26, 2024 8-K

Material AgreementsFinancial EventsExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Executive Changes (Feb 26, 2024)

HCA Healthcare, Inc. (HCA) filed an 8-K on February 26, 2024, detailing its 2024 Executive Officer Performance Excellence Program (Executive Officer PEP). This program establishes performance-based compensation for the company's executive officers, with awards weighted 80% on EBITDA targets and 20% on quality metrics. Specific EBITDA targets will be set for the company overall and for key operating groups, while quality metrics will focus on Healthcare-Associated Infections and Sepsis, Complication and Mortality, and Care Experience. Furthermore, the filing announces an adjustment to the compensation for Michael R. McAlevey, who will transition to Executive Vice President – Chief Legal and Administrative Officer on April 1, 2024. This transition includes a base salary increase and a significant long-term equity incentive award. Notably, William B. Rutherford, Executive Vice President and Chief Financial Officer, will retire on May 1, 2024, and will not participate in the Executive Officer PEP.

Feb 26, 2024 8-K

HCA Healthcare, Inc. 8-K Report, Material Agreement (Feb 23, 2024)

HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing a significant financing transaction. On February 23, 2024, the company, through its subsidiary HCA Inc., successfully completed the public offering of $4.5 billion in aggregate principal amount of senior unsecured notes. These notes are structured across various maturity dates and interest rates, including $1.0 billion of 5.450% notes due 2031, $1.3 billion of 5.600% notes due 2034, $1.5 billion of 6.000% notes due 2054, and $0.7 billion of 6.100% notes due 2064. The parent company, HCA Healthcare, Inc., fully and unconditionally guarantees these notes. This substantial debt issuance, registered under a Form S-3 shelf registration statement, provides HCA with significant capital. The proceeds are intended to fund general corporate purposes, which may include capital expenditures, debt repayment, or acquisitions, although specific use of proceeds is not detailed in this filing. The indenture governing these notes includes standard covenants related to liens, sale and lease-back transactions, and asset disposals, as well as provisions for optional redemption and a change of control repurchase right for noteholders under specific conditions. Investors should note that while these notes are senior unsecured obligations of the issuer, they are effectively subordinated to secured debt and structurally subordinated to the debt and liabilities of HCA's subsidiaries.

Feb 23, 2024 8-K

Earnings & ResultsLeadership ChangesRegulation FD+2

HCA Healthcare, Inc. 8-K Report, Corporate Update (Feb 21, 2024)

HCA Healthcare, Inc. (HCA) announced on February 20, 2024, the execution of an underwriting agreement for the issuance and sale of $4.5 billion in aggregate principal amount of senior notes. This significant debt financing is structured across four tranches with varying maturity dates and interest rates, ranging from 5.450% due in 2031 to 6.100% due in 2064. The notes will be guaranteed on a senior unsecured basis by the parent company, HCA Healthcare, Inc., and are being issued under the company's existing Form S-3 registration statement. This debt offering is a material event for investors as it provides insight into HCA's capital structure management and financing strategy. The substantial capital raised may be intended for various corporate purposes, such as funding operations, acquisitions, refinancing existing debt, or general corporate expenditures. Investors should monitor how these funds are deployed and assess the impact on the company's leverage ratios and overall financial health. The specific terms of the notes, including their coupon rates and maturity profiles, reflect current market conditions and HCA's credit standing.

Feb 21, 2024 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 30, 2024)

HCA Healthcare reported fourth-quarter 2023 revenues of $17.303 billion, up from $15.497 billion a year earlier, with net income attributable to HCA of $1.607 billion, or $5.93 per diluted share, versus $7.28 in 4Q 2022. The comparison is distorted by a $1.326 billion gain on facility sales in 4Q 2022 (worth $2.64 per share); excluding gains and losses on facility sales and debt retirement, 4Q 2023 EPS was $5.90 versus $4.64 a year earlier, a sizable improvement. Adjusted EBITDA rose about 14% to $3.618 billion, with the margin widening to 20.9% from 20.5%. Volume and pricing both contributed: same facility admissions rose 3.1% and revenue per equivalent admission rose 6.9%, reflecting strong demand and improved cost trends. For full-year 2023, revenues were $64.968 billion, Adjusted EBITDA was $12.726 billion, and diluted EPS was $18.97, compared with $19.15 in 2022 (which included large facility-sale gains). The company guided to 2024 revenues of $67.75 to $70.25 billion, Adjusted EBITDA of $12.85 to $13.55 billion, and diluted EPS of $19.70 to $21.20. Capital expenditures are expected at $5.1 to $5.3 billion. The guidance midpoint implies modest EBITDA growth but a higher capital spending burden. Capital allocation remains shareholder-friendly: the Board authorized an additional $6 billion buyback, on top of $775 million remaining at year-end, and declared a $0.66 quarterly dividend. Balance sheet leverage is significant, with total debt of $39.593 billion against cash of $935 million, though the company had $6.107 billion of credit facility availability. Leadership is also changing. CFO Bill Rutherford retires effective May 1, 2024, after ten years as CFO and 34 years with the company. He will be succeeded by Michael A. Marks, a 34-year HCA veteran who is currently Senior Vice President, Finance. Marks's compensation includes a $900,000 base salary and a $2 million target long-term equity award, split between stock appreciation rights and performance share units tied to a three-year cumulative EPS goal. The transition is orderly, with an internal successor who has worked closely with the outgoing CFO, which should reassure investors about continuity.

Jan 30, 2024 8-K

Regulation FDExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Regulation FD Disclosure (Nov 9, 2023)

HCA Healthcare filed this 8-K on November 9, 2023 under Regulation FD to furnish a press release issued ahead of its 2023 Investor Day. The company disclosed its strategic long-term financial targets for the next five years: Adjusted EBITDA growth of 4% to 6% annually and diluted earnings per share growth of 8% to 12% annually. These are presented as composite targets, and management cautioned that results in any single year may fall outside these ranges. Management also gave an early, preliminary view of 2024. CEO Sam Hazen said that while the 2024 planning process was not complete, the company currently believes its 2024 expectations will fall within the long-term target ranges. That view explicitly takes into account the resolution of disputed claims with a commercial payer recorded in the first quarter of 2023, so investors should consider that one-time item when comparing 2024 to prior periods. Detailed 2024 guidance is deferred to the year-end earnings call in January. The filing is largely informational and the material content is forward-looking. Investors should weigh the targets against the risk factors listed in the release, which include payer mix shifts, uninsured patient growth, labor and supply costs, Medicaid and Medicare policy changes, indebtedness, and cybersecurity risk, including the data security incident disclosed in July 2023. The information furnished under Item 7.01 is not deemed filed for Section 18 purposes.

Nov 9, 2023 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Oct 24, 2023)

HCA Healthcare reported third-quarter 2023 revenue of $16.213 billion, up about 8.3% from $14.971 billion a year earlier, driven by solid demand and same-facility growth (admissions up 3.4%, equivalent admissions up 4.1%, revenue per equivalent admission up 3.6%). Profitability was weaker than the top line. Adjusted EBITDA was $2.880 billion versus $2.902 billion, and the Adjusted EBITDA margin fell to 17.8% from 19.4%. Management attributed the shortfall mainly to its Valesco physician staffing joint venture, which underperformed expectations. The quarter also included $397 million of revenue and $195 million of operating expenses tied to the Florida directed payment program year that ended September 30, 2023. Diluted EPS was flat at $3.91, but that figure benefited from a sharp reduction in share count (275.4 million diluted shares versus 289.9 million), as the company repurchased 4.2 million shares for $1.140 billion during the quarter. HCA revised its 2023 guidance. Revenue was narrowed to $63.5–$64.5 billion (from $63.25–$64.75 billion), and net income attributable to HCA was set at $4.940–$5.130 billion (from $4.900–$5.255 billion). Adjusted EBITDA guidance was narrowed to $12.3–$12.6 billion, down from a top end of $12.8 billion, and diluted EPS guidance was narrowed to $17.80–$18.50 (from $17.70–$18.90). The top end of the EBITDA and EPS ranges was lowered, signaling a more cautious outlook for the remainder of the year. The company also declared a quarterly dividend of $0.60 per share, payable December 28, 2023, to holders of record on December 14, 2023. Balance sheet and cash flow metrics were mixed. Third-quarter operating cash flow was $2.479 billion, down from $3.020 billion a year earlier. Capital expenditures were $1.147 billion. Total debt was $39.346 billion against cash of $891 million, and the company had $6.455 billion of credit facility availability. The filing also references a data security incident disclosed in July 2023 among its forward-looking risk factors.

Oct 24, 2023 8-K

HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 27, 2023)

HCA Healthcare reported second-quarter 2023 revenues of $15.861 billion, up about 7.0% from $14.820 billion a year earlier. Net income attributable to HCA rose to $1.193 billion, or $4.29 per diluted share, versus $3.90 in 2Q 2022. The EPS increase is helped by the absence of the prior-year losses on facility sales ($0.11) and debt retirement ($0.20), and by a diluted share count that fell to 278.2 million from 296.1 million after buybacks. Excluding those prior-year items, EPS grew from $4.21 to $4.29. Adjusted EBITDA was $3.056 billion, roughly flat with $3.042 billion, and the Adjusted EBITDA margin contracted to 19.3% from 20.5%. That margin compression reflects the cost pressures visible in the income statement: salaries and benefits, supplies, and other operating expenses all grew faster than revenue as a share of sales. Volume trends were solid. Same-facility admissions rose 2.2%, same-facility equivalent admissions rose 3.7%, and same-facility emergency room visits rose 3.7%. Same-facility revenue per equivalent admission increased 2.4%. Operating cash flow was strong at $2.475 billion in the quarter, compared with $1.630 billion a year earlier. HCA repurchased 3.3 million shares for $915 million in the quarter, with $2.825 billion left under its authorization, and declared a $0.60 quarterly dividend payable September 29, 2023. Total debt stood at $38.932 billion at quarter-end, so leverage remains the key balance sheet consideration. Management raised full-year 2023 guidance. Revenue is now expected at $63.25 to $64.75 billion (from $62.5 to $64.5 billion), Adjusted EBITDA at $12.3 to $12.8 billion (from $12.1 to $12.7 billion), and diluted EPS at $17.70 to $18.90 (from $17.25 to $18.55). Capital expenditures are now estimated at about $4.7 billion, up from $4.6 billion. The forward-looking statements also reference a data security incident disclosed in July 2023, which investors should monitor for any financial or operational impact.

Jul 27, 2023 8-K

HCA Healthcare, Inc. 8-K Report, Corporate Update (Jul 10, 2023)

On July 10, 2023, HCA Healthcare disclosed in an 8-K (Item 8.01, with the press release furnished as Exhibit 99.1) a data security incident in which a list of certain patient information was posted by an unknown, unauthorized party on an online forum. The exposed data includes patient name, city, state, and zip code; email, telephone number, date of birth, and gender; and patient service date, location, and next appointment date. HCA states the list does not include clinical information (treatment, diagnosis, condition), payment information (credit card or account numbers), or sensitive identifiers such as passwords, driver's license numbers, or Social Security numbers. HCA attributes the incident to theft from an external storage location used exclusively to automate the formatting of patient email messages. The company says there has been no disruption to patient care, services, or day-to-day operations, and it has not identified malicious activity on its own networks or systems related to the incident. It reported the matter to law enforcement, retained third-party forensic and threat intelligence advisors, and disabled user access to the storage location as containment. HCA said that, based on information known at the time, it does not believe the incident will materially affect its business, operations, or financial results. For investors, the filing is primarily a disclosure event rather than a financial one. The filing contains no quantified cost estimates, reserves, or insurance recovery figures. The main forward-looking risks flagged include the scope of the incident, potential claims, litigation, and regulatory proceedings, incremental incident-response expenses, the availability of insurance coverage, and reputational harm. The investigation was ongoing at the time of filing, so the scope and any associated costs could change.

Jul 10, 2023 8-K

Material AgreementsFinancial EventsExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Corporate Update (May 26, 2023)

On May 26, 2023, HCA Healthcare filed this Form 8-K to recast its historical segment reporting in Note 13 of the 2022 Form 10-K. Effective January 1, 2023, HCA reorganized its operations from two geographic groups (National and American) into three (National, American and Atlantic). The filing does not reclassify or restate any consolidated financial statements, and the consolidated figures for 2022 are unchanged: revenues of $60.233 billion, net income attributable to HCA of $5.643 billion, diluted EPS of $19.15, and operating cash flow of $8.522 billion. The change is presentational, so the economic results of the business are unaffected. Under the new structure, 2022 revenues were $16.767 billion for the National Group, $19.324 billion for the Atlantic Group and $20.858 billion for the American Group, with Corporate and other at $3.284 billion. Adjusted segment EBITDA was $3.616 billion for National, $3.881 billion for Atlantic and $5.102 billion for American, against a corporate drag of $(532) million. Investors should note that the Atlantic Group, which now includes Florida, Georgia and South Carolina, is a larger and more distinct reporting unit than before, which gives better visibility into the performance of HCA's Southeast footprint. The filing also confirms the 2022 capital structure and cash flow profile that matter for valuation and credit analysis. Total long-term debt was $38.084 billion at year-end 2022, and capital expenditures were $4.395 billion. Share repurchases totaled $7.0 billion in 2022, and distributions to noncontrolling interests were $1.025 billion. Ernst & Young issued its audit report with an updated date for Note 13, and it reiterated its critical audit matters on revenue recognition and professional liability claims.

May 26, 2023 8-K

HCA Healthcare, Inc. 8-K Report, Material Agreement (May 4, 2023)

HCA Healthcare, Inc. (HCA) announced the completion of a significant public offering of senior unsecured notes totaling $3.25 billion on May 4, 2023. This offering comprises three tranches: $1 billion in 5.200% Senior Notes due 2028, $1.25 billion in 5.500% Senior Notes due 2033, and $1 billion in 5.900% Senior Notes due 2053. These notes are issued by HCA Inc., a wholly owned subsidiary, and are guaranteed on a senior unsecured basis by the parent company, HCA Healthcare, Inc. The proceeds from this issuance are intended to fund general corporate purposes. This move diversifies HCA's debt maturity profile and provides substantial capital. From an investor's perspective, this filing indicates the company's proactive management of its capital structure and its ability to access public debt markets efficiently. The guaranteed nature of the notes by the parent company offers a strong layer of credit support. While the new debt increases HCA's overall leverage, the company has outlined standard covenants that aim to protect noteholders, including restrictions on liens, sale-leaseback transactions, and asset disposals. The inclusion of a change of control provision with a premium repurchase price for noteholders also provides a measure of protection against significant unfavorable corporate events.

May 4, 2023 8-K

HCA Healthcare, Inc. 8-K Report, Corporate Update (May 2, 2023)

HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing a significant debt issuance. On May 1, 2023, the company, through its wholly-owned subsidiary HCA Inc., entered into an underwriting agreement to issue and sell $3.25 billion in senior notes. This offering is comprised of three tranches: $1 billion of 5.200% Senior Notes due 2028, $1.25 billion of 5.500% Senior Notes due 2033, and $1 billion of 5.900% Senior Notes due 2053. The Notes will be senior unsecured obligations, guaranteed by HCA Healthcare, Inc. The issuance is being conducted under the company's effective registration statement on Form S-3. This action signals a strategic move by HCA to raise substantial capital, likely to fund ongoing operations, potential acquisitions, or refinance existing debt under potentially more favorable terms. Investors should note the varying interest rates and maturity dates across the different tranches.

May 2, 2023 8-K

Leadership ChangesShareholder MattersExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Financial Results (Apr 21, 2023)

HCA Healthcare reported first quarter 2023 results that beat the prior-year period on most measures and raised its full-year 2023 guidance. Revenues rose 4.3% to $15.591 billion from $14.945 billion, and net income attributable to HCA rose to $1.363 billion, or $4.85 per diluted share, versus $4.14 a year earlier. Adjusted EBITDA increased to $3.172 billion from $2.944 billion, with the margin expanding to 20.3% from 19.7%. Results were helped by a $145 million revenue recognition (about $0.40 per diluted share) from resolving disputed claims from prior years with a commercial payer, so underlying growth is somewhat lower than the headline figures suggest. Volume trends were strong: same facility admissions rose 4.4% and equivalent admissions rose 7.5%, while same facility revenue per equivalent admission fell 2.3%, largely because COVID-19 volumes and reimbursement were higher in the prior-year quarter. The company raised 2023 guidance across all key metrics. Revenue is now expected at $62.5 to $64.5 billion (up from $61.5 to $63.5 billion), net income attributable to HCA at $4.750 to $5.160 billion, Adjusted EBITDA at $12.1 to $12.7 billion, and diluted EPS at $17.25 to $18.55. Capital expenditures are estimated at about $4.6 billion for 2023. Note that the guidance raise is a meaningful part of the EPS increase, and the revised EPS range is partly supported by the one-time payer settlement recognized in Q1. Balance sheet and capital return items were mixed. Cash and equivalents were $842 million and total debt was $38.856 billion, with $2.378 billion of long-term debt due within one year. HCA repurchased 3.34 million shares for $846 million in the quarter and retains $3.740 billion under repurchase authorizations. Operating cash flow was $1.803 billion, up from $1.345 billion, though a large part of the year-over-year improvement reflects working capital movements. The Board declared a quarterly dividend of $0.60 per share, payable June 30, 2023 to holders of record on June 16, 2023.

Apr 21, 2023 8-K

HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 21, 2023)

HCA Healthcare, Inc. (HCA) filed an 8-K on April 21, 2023, reporting the results of its Annual Meeting of Stockholders held on April 19, 2023. The primary focus of this filing is the outcome of various shareholder votes, including the election of directors, ratification of auditors, and approval of corporate plans. Notably, all ten director nominees were elected with substantial support, indicating shareholder confidence in the current leadership. The company's 2023 Employee Stock Purchase Plan also received strong approval from stockholders, signaling support for employee ownership and engagement initiatives. The filing also confirms the ratification of Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year, a standard but crucial vote for financial oversight. Additionally, shareholders approved an advisory resolution on executive compensation, reflecting general satisfaction with the company's compensation practices. Conversely, two shareholder proposals, one concerning political spending disclosure and another regarding an amendment to the Patient Safety and Quality of Care Committee charter, did not receive majority approval.

Apr 21, 2023 8-K

HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 6, 2023)

HCA Healthcare, Inc. (HCA) has filed an 8-K detailing its new 2023 Senior Officer Performance Excellence Program (Senior Officer PEP). This program outlines the incentive compensation structure for the company's executive officers, with awards weighted 80% towards EBITDA targets and 20% towards quality metrics. The program aims to align executive compensation with both financial performance and patient care quality. Key features include tiered payout structures for performance against targets, with specific award opportunities outlined for the CEO, CFO, COO, and Chief Legal Officer, expressed as percentages of their base salaries. The program also includes provisions for adjustments, clawbacks in certain circumstances, and is payable in cash. Investors should note the emphasis on EBITDA and specific quality indicators, which provides insight into HCA's strategic priorities for executive performance in 2023.

Apr 6, 2023 8-K/A

Leadership Changes

HCA Healthcare, Inc. 8-K/A Report, Executive Changes (Jan 30, 2023)

This 8-K Amendment from HCA Healthcare, Inc. (HCA) provides crucial updates on the compensation package for its newly appointed Executive Vice President and Chief Operating Officer, Jon M. Foster. While the initial appointment was announced in October 2022, this filing details material changes to Mr. Foster's compensation, approved by the Compensation Committee in January 2023. The key changes include an increase in base salary and a significant long-term equity incentive award, signaling the company's investment in key executive talent for its operational leadership. Investors should note the details of Mr. Foster's enhanced compensation, which includes a base salary adjustment to $1,000,000 and a substantial equity grant valued at $3,750,000. This equity award is structured with a mix of stock appreciation rights and performance share units, aligning a significant portion of his compensation with long-term company performance and shareholder value. This filing clarifies compensation details that were undetermined at the time of the initial appointment announcement.

Jan 30, 2023 8-K

Material AgreementsExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 27, 2023)

HCA Healthcare reported fourth-quarter and full-year 2022 results on January 27, 2023, with revenue growing modestly but earnings heavily flattered by asset sales. Q4 2022 revenue was $15.497 billion (up from $15.064 billion), and net income attributable to HCA was $2.081 billion, or $7.28 per diluted share, versus $5.75 a year earlier. That headline figure includes $1.326 billion ($2.64 per share) of gains on sales of facilities. Excluding those gains and debt-retirement losses, full-year 2022 EPS was $16.89 versus $17.50 in 2021, and Adjusted EBITDA fell to $12.067 billion from $12.644 billion, with the margin compressing to 20.0% from 21.5%. Q4 Adjusted EBITDA was roughly flat at $3.179 billion versus $3.149 billion. Operating volumes were mixed: same facility admissions rose 2.9%, emergency room visits rose 11.4%, and same facility revenue per equivalent admission declined 2.6%, partly reflecting lower COVID-19 volumes compared with the prior year. Hurricane Ian cost roughly $50 million before insurance recoveries. Capital return remains a central part of the story. HCA repurchased 6.781 million shares for $1.519 billion in Q4, and the Board authorized an additional $3 billion buyback with no time limit. The quarterly dividend was set at $0.60 per share, payable March 31, 2023. Full-year 2022 share repurchases of $7.0 billion and dividend payments of $653 million were funded largely by operating cash flow of $8.522 billion. Net debt rose with total debt of $38.084 billion against cash of $908 million, and the company held $3.535 billion of credit facility availability. For 2023, management guided to revenue of $61.5 to $63.5 billion, net income attributable to HCA of $4.525 to $4.895 billion, Adjusted EBITDA of $11.8 to $12.4 billion, and diluted EPS of $16.40 to $17.60 on about 278 million shares. Capital expenditures are expected to be about $4.3 billion. The EPS guidance excludes asset-sale gains and other non-recurring items, and the midpoint implies a decline in Adjusted EBITDA from 2022, so investors should weigh the company's earnings trajectory against its buyback pace.

Jan 27, 2023 8-K

HCA Healthcare, Inc. 8-K Report, Material Agreement (Jan 4, 2023)

HCA Healthcare, Inc. (HCA) announced significant updates to its credit facilities through amendments and restatements filed on January 4, 2023. The primary focus of these changes involves the transition from LIBOR to Term SOFR as the benchmark interest rate for both its senior secured credit facility (Cash Flow Credit Facility) and its senior secured asset-based revolving credit facility (ABL Credit Facility). This transition is a critical step for HCA to align with evolving market standards and regulatory requirements, ensuring continued access to credit in a post-LIBOR environment. In addition to the benchmark rate transition, HCA has substantially increased its revolving credit capacity. The Cash Flow Credit Facility's revolving commitments have been expanded from $2.0 billion to $3.5 billion, maturing on June 30, 2026. This enhancement to its liquidity provides greater financial flexibility. Furthermore, HCA utilized proceeds from new ABL Credit Facility borrowings, combined with existing cash, to fully repay its $492.5 million in outstanding Tranche B term loans. These actions demonstrate proactive debt management and a strategic strengthening of the company's financial structure.

Jan 4, 2023 8-K

Corporate ChangesExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Bylaw Amendment (Dec 19, 2022)

This 8-K filing from HCA Healthcare, Inc. (HCA) announced an update to the company's bylaws, effective December 19, 2022. The Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee, adopted the Third Amended Bylaws. This amendment primarily focuses on updating provisions related to director nominations and proxy solicitations to align with current regulations, specifically requiring compliance with Rule 14a-19 of the Securities Exchange Act of 1934. While this filing does not contain significant financial information or operational changes, investors should note the proactive steps HCA is taking to ensure its corporate governance practices are up-to-date with regulatory requirements. The changes are described as technical, ministerial, clarifying, and conforming, suggesting a focus on maintaining compliance and good governance rather than a shift in strategic direction or financial performance.

Dec 19, 2022 8-K

Leadership ChangesRegulation FDExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Executive Changes (Oct 26, 2022)

HCA Healthcare's October 26, 2022 8-K reports an operational reorganization rather than a financial result. Effective January 1, 2023, HCA is creating a third operating group, with five domestic divisions in each of the three groups, to improve strategic alignment, streamline operations, and speed decision-making. The filing's main personnel change is the appointment of Jon M. Foster, currently President of the American Group, as Executive Vice President and Chief Operating Officer. He will oversee growth and operational support areas, including Development, Payer Contracting & Alignment, Strategy & Innovation, Service Lines, Ambulatory Surgery, Physician and Provider Relations, and the UK Division. Mike Marks is promoted to Senior Vice President-Finance and will oversee Parallon, Case Management, Performance Improvement, and the financial resiliency program. The reorganization also creates a new Atlantic Group under Richard Hammett, covering a newly created hospital group, and reshuffles group presidents and CFOs. Erol Akdamar becomes President of the American Group, Tim McManus becomes President of the National Group after Chuck Hall's previously announced retirement, and the Atlantic Group structure is set out in the release. Several division president and CFO changes are also announced. For investors, the filing contains no financial results, guidance, or quantified cost or savings estimates. Foster's compensation has not yet been determined, and the filing says the required Item 5.02(c)(2) information is incorporated by reference from prior filings. The most relevant takeaways are the leadership succession signal, the restructuring of operating oversight, and the open question of how the new structure will affect execution and costs.

Oct 26, 2022 8-K